Incyte announced results from the Phase 3 POD1UM-303/InterAACT2 study of retifanlimab, a humanized monoclonal antibody directed …
Incyte announced results from the Phase 3 POD1UM-303/InterAACT2 study of retifanlimab, a humanized monoclonal antibody directed …